Novel ctla4-ig immunoadhesins
US-2016264643-A1 · Sep 15, 2016 · US
Antibody Fc mutants with ablated effector functions
US9637549B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9637549-B2 |
| Application number | US-201514597690-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 15, 2015 |
| Priority date | Nov 30, 2009 |
| Publication date | May 2, 2017 |
| Grant date | May 2, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
First claim
Opening claim text (preview).
What is claimed: 1. A method of altering binding of an IgG2 based Fc-containing molecule to Fcγ receptors as compared to a wildtype IgG2 based Fc, comprising altering the sequence of an Fc domain based on an IgG2 constant region at residues 233, 234, 235, 237, and 238 defined by the EU numbering system, to comprise a sequence selected from PAAAS (SEQ ID NO:5) and SAAAS (SEQ ID NO:6), and altering the IgG2 based Fc-containing molecule to further comprise mutations H268A or H268Q, V309L, A330S and P331S, wherein the binding of the IgG2 based Fc-containing molecule to Fcγ receptors is reduced as compared to a wildtype IgG2 based Fc.
Assignees
Inventors
Classifications
Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
- C07K16/32Primary
against translation products of oncogenes · CPC title
against receptors, cell surface antigens or cell surface determinants · CPC title
- C07K16/00Primary
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9637549B2 cover?
- Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).